The FDA (Food and Drug Administration) and EMA (European Medicines Agency) already approved several low molecular tyrosine kinase inhibitors (gefitinib, erlotinib, afatinib, and osimertinib) as first line treatment for sensitive EGFR-mutant patients with non-small-cell lung cancer (NSCLC) [23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.